Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12...4567891011121314...2425»
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] How the COVID-19 Pandemic Has Changed Multiple Sclerosis Clinical Practice: Results of a Nationwide Provider Survey (BUTLER) -  Oct 8, 2021 - Abstract #CMSC2021CMSC_149;    
    DMTs prescribed less often included alemtuzumab (64.2%), cladribine (52.4%), and B cell-depleting agents including ocrelizumab and rituximab (50%). In this nationwide survey, MS specialist physicians and other clinicians serving on regional NMSS Healthcare Provider Councils across the US reported profound changes in how they are delivering MS care during the COVID-19 pandemic.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Baló's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases. (Pubmed Central) -  Oct 7, 2021   
    Fingolimod should likely be avoided as Baló-like lesions have been reported during its administration or after withdrawal. Monoclonal antibodies such as natalizumab and rituximab are potentially effective at reducing BCS relapses, but alemtuzumab may be relatively ineffective because humoral immunity does not play a central role in BCS pathogenesis.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  HUMORAL RESPONSE TO SARS-CoV-2 AND COVID-19 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH IMMUNE RECONSTITUTION THERAPIES. (Pubmed Central) -  Oct 7, 2021   
    Monoclonal antibodies such as natalizumab and rituximab are potentially effective at reducing BCS relapses, but alemtuzumab may be relatively ineffective because humoral immunity does not play a central role in BCS pathogenesis. Our findings in a small number of highly active PwMS in whom, lymphodepleting, immune reconstitution therapies, were applied in order to successfully manage MS, indicate that in a number of these patients it was possible to develop at the same time seroprotection in these patients after COVID-19 vaccination in these complex circumstances.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Ponvory (ponesimod) / J&J, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Ponesimod (Ponvory) for multiple sclerosis. (Pubmed Central) -  Oct 7, 2021   
    Our findings in a small number of highly active PwMS in whom, lymphodepleting, immune reconstitution therapies, were applied in order to successfully manage MS, indicate that in a number of these patients it was possible to develop at the same time seroprotection in these patients after COVID-19 vaccination in these complex circumstances. No abstract available
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Enrollment closed:  LEMTRADA Pregnancy Registry in Multiple Sclerosis (clinicaltrials.gov) -  Oct 4, 2021   
    P=N/A,  N=204, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Alemtuzumab mediates the CD T-regulatory response via CD23 macrophages. (Pubmed Central) -  Sep 30, 2021   
    ALM induces monocytes' conversion into anti-inflammatory macrophages, which in turn promote T-regulatory enhancement, in a CD23 dependent manner. These findings suggest the mechanism of action of ALM is relevant to aspects of MS pathogenesis.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis. (Pubmed Central) -  Sep 29, 2021   
    In treated patients with SPMS, high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active, but not those with inactive, SPMS. However, more potent therapies do not offer an advantage in reducing disability progression in this patient group.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data. (Pubmed Central) -  Sep 26, 2021   
    Prevalence was estimated by dividing the total number of monthly prescriptions by 12 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates...From 2010 to 2017 using the median latitudes for each state/territory, the overall latitudinal variation in MS prevalence was an increase of 3.0% per degree-latitude. Consistent with global trends, Australia's MS prevalence has increased; this probably reflecting decreased mortality, increased longevity and increased incidence.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Elevated D-dimer as an immediate response to alemtuzumab treatment. (Pubmed Central) -  Sep 26, 2021   
    This observation provides evidence of coagulation activation and the potential risk of thrombotic complications with this therapy. Prophylactic low molecular weight heparin pretreatment maybe considered in patients receiving alemtuzumab.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Alemtuzumab-related eosinophilic central nervous system vasculitis. (Pubmed Central) -  Sep 26, 2021   
    The patient was treated successfully with cyclophosphamide. The potential sequelae of alemtuzumab treatment are discussed; this treatable complication should be considered when tests for JC virus are negative.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Review, Journal, HEOR:  Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review. (Pubmed Central) -  Sep 24, 2021   
    The present paper shows that cost-effectiveness studies have high levels of methodological variability, some of them  reaching contradictory results. As a result, it is not possible to  determine which disease- modifying therapy is really cost-effective in  the context of relapsingremitting multiple sclerosis.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Long-term immune-related adverse events after alemtuzumab (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2615;    
    The autoimmune adverse events are probably related to immune dysregulation due to a differential lymphocyte repopulation following alemtuzumab. Autoimmune adverse events may be frequent, and it would be recommended to monitor its appearance in order to diagnose and treat them.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Novel immunological effects of alemtuzumab therapy in multiple sclerosis (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2522;    
    From these findings we confirm that alemtuzumab treatment profoundly alters circulating lymphocyte phenotype. The relationship between disease activity and secondary autoimmunity and these changes, including the novel observation of T cell exhaustion and changes in the Tfh-Tfr compartment, is addressed in an ongoing follow-up study.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Novel immunological effects of alemtuzumab therapy in multiple sclerosis (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2521;    
    From these findings we confirm that alemtuzumab treatment profoundly alters circulating lymphocyte phenotype. The relationship between disease activity and secondary autoimmunity and these changes, including the novel observation of T cell exhaustion and changes in the Tfh-Tfr compartment, is addressed in an ongoing follow-up study.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Humoral immune response after COVID-19 in multiple sclerosis: a nation-wide Austrian study (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2454;    
    Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly antiCD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing of vaccination.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Humoral immune response after COVID-19 in multiple sclerosis: a nation-wide Austrian study (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2453;    
    Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly antiCD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing of vaccination.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Relapse reduction by disease-modifying therapies for relapsing multiple sclerosis: A network meta‑analysis (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2448;    
    Recently, several novel DMTs including ofatumumab, ozanimod, and ponesimod were approved for the treatment of RMS in the United States and/or Europe... Ofatumumab was identified as a highly effective treatment option for reducing relapse risk in patients with RMS among both contemporary and older DMTs.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    [VIRTUAL] Cladribine in a real world setting. The real patients (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2409;    
    23 patients switch from teriflunomide, 16 from dimethylfumarate, 14 from fingolimod, 22 from injectables, 1 from alemtuzumab... In the real world cladribine has proved to be effective, safe and very well tolerated.